• Home
  • About Us
  • Blog
  • Contact Us

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Uptravi is Approved for PAH Treatment
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Congenital Heart Disease
    • Eisenmenger’s Syndrome
    • Update on Management of PAH-CHD
    • Congenital Heart Disease & Sleep Apnea
    • Complex Congenital Heart Disease
    • Atrial Septal Defect and Pulmonary Arterial Hypertension
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH

Increased Interest in PAH: What it Means for Patients

July 24, 2017 By Dr. Jeremy Feldman

pah pills

As more and more treatments become available for PAH and more patients are diagnosed and living with this chronic and progressive disease, there seems to be more and more news of biopharmaceutical companies jumping on board to develop and eventually sell treatments for PH.  It seems nearly every day there is a headline stating companies have merged or been purchased or even started in order for them to develop better treatments for PAH. Examples such as “Icagen and Omdana Are Collaborating on Pulmonary Hypertension Therapies” or “Johnson & Johnson Completes Acquisition of Actelion, a Leader in Pulmonary Hypertension Therapies” are now common in our news feeds. So what does this mean for pulmonary hypertension patients?

The World Is More Aware

We used to think that pulmonary arterial hypertension was a very rare disease and most physicians would see or identify very few cases during their entire careers. As the world becomes more aware of the disease, more cases are identified and treated. Although misdiagnosis and mistreatment of the disease is still a huge problem, more and more patients are being correctly diagnosed and being sent to PAH Comprehensive Care Centers for treatment. The best chance for slowing down or reversing pulmonary hypertension is early diagnosis and treatment. Increased awareness directly impacts the number of patients being treated and living with PAH.

There is Money to Be Made in Developing Treatments for PAH

As the number of patients being diagnosed has increased, so has the number of prescriptions being written for treating PAH. It is very expensive to develop a therapy for rare diseases and many pharmaceutical companies find it too risky to invest the capital in research that may or may not turn into an effective therapy. The increased number of prescriptions being written leads pharmaceutical companies to be more willing to invest in research as the payoff could be greater than previously thought. There is a larger patient pool that could potentially be on their therapies. This is beneficial to PAH patients, as more research being done in PH will hopefully lead to more effective therapies and hopefully one day a cure.

How Can PAH Patients Benefit from Increased Bio-Pharmaceutical Interest in PAH?

In order for patients currently living with PAH to benefit from increased interest by biopharmaceutical companies they need to be informed and aware. Keep regular appointments with your PH Specialist and stay up to date by reading blogs like ours. Increased interest will lead to new research studies. Participating in research can be an excellent opportunity to receive new treatments and sometimes FDA approved treatments. The treatments are usually free and participants may even receive a small stipend for their time and travel.  Frequent appointments with the research team and sometimes a PAH expert may also be provided.

Filed Under: Healthcare Costs

Advertisement

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Advertisement

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

PAH Expert talking with PH patient

Second Opinions

By Dr. Jeremy Feldman

I can’t tell you how frequently my patients ask if their doctor will be offended if the patient goes to a different

PAH treatment team

Who’s Who at your Pulmonary Hypertension Center

By Dr. Jeremy Feldman

The first visit at a PH center can be very overwhelming. Many patients receive the news that they have a serious life

The Doctor is In

  • Facebook
  • Google+
  • RSS
  • Twitter

Get Our Newsletter!

good news in pah

Recent Blog Posts

  • Pulmonary Hypertension Due To Valvular Heart Disease October 29, 2019
  • A New Approach to Treating Pulmonary Arterial Hypertension October 23, 2019
  • Scleroderma: Screening for Pulmonary Hypertension October 10, 2019

Categories

Archives

Copyright © 2019 Inspire Pulmonary Media, LLC